NTRBW 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-09-04

• Item 3 Quantitative and Qualitative Disclosures about Market Risk 24

相对上期删除的文字 · 来源:10-Q · 2026-06-11

• This report contains forward-looking statements regarding our business, financial condition, results of operations and prospects. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify …

• Although forward-looking statements in this report reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcom…

• We undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date of this report, except as required by law. Readers are urged to carefully review and consider the various disclosures made throughout the entirety of this …

• Nutriband Inc. (the “Company”, “Nutriband”, “we” or “us”), was incorporated in Nevada in January 2016. Our primary business is the development of a portfolio of transdermal pharmaceutical products. Our development pipeline primarily consists of transdermal products that are based on our proprietary …

• The Company’s revenues are based on providing services through our subsidiaries Pocono Pharmaceuticals operating as Active Intelligence and 4P Therapeutics. Pocono Pharmaceuticals provides contract manufacturing services for health, wellness and over-the-counter pharmaceutical customers and 4P Thera…

相对上期新增的文字 · 来源:10-Q · 2026-09-04

• Number of Number of Paid In Comprehensive Accumulated Treasury

• Total shares Amount shares Amount Capital Income(Loss) Deficit Stock

• Number of Number of Paid In Comprehensive Accumulated Treasury

• Total shares Amount shares Amount Capital Income(Loss) Deficit Stock

• Proceeds from the exercise of employee stock options - 44,206

相对上期删除的文字 · 来源:10-Q · 2026-06-11

• Net loss per share attributable to common stockholders - basic and diluted $(0.10) $(0.12)

• Weighted average common shares outstanding - basic and diluted 12,155,983 11,125,800

• Proceeds from sale of common stock and exercise of warrants - -

• as of and for the Three Months Ended April 30, 2026 and 2025

• The Company’s revenues include significant concentration from a limited number of customers. For the three months ended April 30, 2026, Customer A, Customer B, Customer C, and Customer D accounted for approximately 25%, 20%, 14%, and 10% of the Company’s total consolidated revenues.